Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04486716 · ClinicalTrials.gov registry record · Phase 3
A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 111
- Enrollment target
NCT04486716 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 111 participants.
The verdict
NCT04486716, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 111 participants
- Enrollment target
Study Summary
A single arm study evaluating the continued efficacy, safety and tolerability of ofatumumab in patients with relapsing multiple sclerosis who are transitioning from aCD20 mAb therapy
Interventions
- DRUG Ofatumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2020-10-19 |
| Est. Completion | 2024-10-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04486716
The ClinicalTrials.gov registry entry for NCT04486716 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ofatumumab is the first listed.
NCT04486716 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04486716 about?
NCT04486716 is a clinical study titled "A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis". A single arm study evaluating the continued efficacy, safety and tolerability of ofatumumab in patients with relapsing multiple sclerosis who are transitioning from aCD20 mAb therapy
What is the current status of trial NCT04486716?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 111 participants. The study started on 2020-10-19. Estimated completion is 2024-10-21.
What interventions are being tested in trial NCT04486716?
The interventions under investigation include: Ofatumumab (DRUG).
Who is sponsoring clinical trial NCT04486716?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.